These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35324914)

  • 21. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
    Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
    Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.
    Cimino PJ; Bredemeyer A; Abel HJ; Duncavage EJ
    Exp Mol Pathol; 2015 Jun; 98(3):568-73. PubMed ID: 25910966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma.
    Wrzeszczynski KO; Felice V; Shah M; Rahman S; Emde AK; Jobanputra V; O Frank M; Darnell RB
    Methods Mol Biol; 2018; 1741():1-29. PubMed ID: 29392687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
    Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
    Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward Precision Oncology in Glioblastoma with a Personalized Cancer Genome Reporting Tool and Genetic Changes Identified by Whole Exome Sequencing.
    Erdogan O; Özkaya ŞÇ; Erzik C; Bilguvar K; Arga KY; Bayraklı F
    OMICS; 2023 Sep; 27(9):426-433. PubMed ID: 37669106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
    Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
    Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical target sequencing for precision medicine of breast cancer.
    Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
    Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequencing the next generation of glioblastomas.
    Jovčevska I
    Crit Rev Clin Lab Sci; 2018 Jun; 55(4):264-282. PubMed ID: 29668342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The possibility of clinical sequencing in the management of cancer.
    Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
    Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
    Mahlokozera T; Vellimana AK; Li T; Mao DD; Zohny ZS; Kim DH; Tran DD; Marcus DS; Fouke SJ; Campian JL; Dunn GP; Miller CA; Kim AH
    Neuro Oncol; 2018 Mar; 20(4):472-483. PubMed ID: 29244145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
    Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
    Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of genomic biomarkers and their pathway crosstalks for deciphering mechanistic links in glioblastoma.
    Quddusi DM; Bajcinca N
    IET Syst Biol; 2023 Aug; 17(4):143-161. PubMed ID: 37277696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.